• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

ERT Appoints New Vice President of Project Management

Posted on: Wednesday, 22 July 2009, 09:00 CDT

PHILADELPHIA, July 22 /PRNewswire-FirstCall/ -- ERT (Nasdaq: ERES), a leading provider of centralized ECG and eClinical technology, ePRO, and other services to the biopharmaceutical, medical device, and related industries, announced the appointment of a new Vice President of Project Management, Tammy Miller. Ms. Miller will report to the Executive Vice President of Cardiac Safety Operations. In this new role, Ms. Miller will be responsible for the global implementation and delivery of ERT's Project Assurance methodology, including developing and executing strategic plans to maximize customer service excellence.

Ms. Miller has 24 years' experience of working in the health care industry, with 12 years in the CRO and pharmaceutical industry. She has an MBA in Global Management from the University of Phoenix and has built up extensive project management experience, including scenario building, forecasting, budgeting resource allocation, and timeline management. Ms. Miller joins ERT from Quintiles Inc where she worked as Group Director for CNS.

ERT's unique Project Assurance methodology is an SOP-driven approach that proactively addresses the full range of support functions required to ensure the success of a clinical study. The ERT focus on project management and operational excellence ensures global consistency, reliable data collection, and customer satisfaction. The global Project Management team works closely with the Cardiac Safety and Customer Care teams.

Amy Furlong, EVP, Cardiac Safety Operations at ERT, said, "With Tammy's extensive experience in the industry, we are confident she will be a key member of our senior management team. Our decision to appoint Tammy as Vice President, Project Management, demonstrates our continued commitment to delivering operational excellence to our customers."

Amy added, "In recent years, the Company has grown significantly in terms of scale and reputation, and with this appointment, we plan to continue to grow from strength to strength. We are delighted to welcome Tammy to the ERT team."

ERT is a leading provider of technology and services to the biopharmaceutical and medical device industries around the world. The key areas of ERT products and services - ERT Cardiac Safety Solutions, ERT ePRO Solutions, and ERT Clinical Research Consulting Group - are all enabled by the Company's innovative technology platform - EXPERT(TM). EXPERT is a robust, secure, and validated clinical research workflow-processing system that powers centralized electronic data collection, data management, and information exchange.

For further information on ERT and its technology and services, please email info@ert.com, call +1 215 972 0420 or visit www.ert.com.

For further press information, please contact Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, Email ert@scottpr.co.uk

About ERT

Based in Philadelphia, PA, ERT (eResearchTechnology, Inc.) (www.ert.com) is a provider of technology and services to the global biopharmaceutical and medical device industries. The Company is the market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The Company also provides technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including, but not limited to, 2009 financial guidance, involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE ERT

Source: PR Newswire

More News in this Category